Prolongation and expansion of agreement with TRT Innovations ApS
Today, the 7 October, 2020, Curasight A/S (“Curasight” or the “Company”) has entered into an expansion of the agreement with TRT Innovations ApS (“TRT Innovations”), which ensures the right for the Company to broaden its activities within targeted radionuclide therapy in cancer. Inlägget Prolongation and expansion of agreement with TRT Innovations ApS dök först upp på IPO. se.